Summit Therapeutics PLC(SMMT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SMMT Summit Therapeutics PLC

盘前交易 06-10 08:03:37 EDT

14.29

+0.18

+1.28%

盘前13.26

-1.03-7.21%

07:59 EDT

最高14.68	最低14.02	成交量503.49万
今开14.47	昨收14.11	日振幅4.68%
总市值110.80亿	流通市值18.43亿	总股本7.75亿
成交额7,219万	换手率3.90%	流通股本1.29亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"SMMT","market":"US","secType":"STK","nameCN":"Summit Therapeutics PLC","latestPrice":14.29,"timestamp":1781035200000,"preClose":14.11,"halted":0,"volume":5034913,"hourTrading":{"tag":"盘前","latestPrice":13.26,"preClose":14.29,"latestTime":"07:59 EDT","volume":8381,"amount":111212.09855000001,"timestamp":1781092768892,"change":-1.03,"changeRate":-0.072078,"amplitude":0.03359},"delay":0,"changeRate":0.012756909992912808,"floatShares":129000000,"shares":775372700,"eps":-1.593158,"marketStatus":"盘前交易","change":0.18,"latestTime":"06-10 08:03:37 EDT","open":14.47,"high":14.68,"low":14.02,"amount":72188432.686149,"amplitude":0.046775,"askPrice":13.7,"askSize":200,"bidPrice":13.2,"bidSize":110,"shortable":3,"etf":0,"ttmEps":-1.593158,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781098200000},"marketStatusCode":1,"adr":1,"adrRate":5,"listingDate":1425531600000,"exchange":"NASDAQ","adjPreClose":14.29,"preHourTrading":{"tag":"盘前","latestPrice":13.26,"preClose":14.29,"latestTime":"07:59 EDT","volume":8381,"amount":111212.09855000001,"timestamp":1781092768892,"change":-1.03,"changeRate":-0.072078,"amplitude":0.03359},"postHourTrading":{"tag":"盘后","latestPrice":13.29,"preClose":14.29,"latestTime":"19:59 EDT","volume":274942,"amount":3721578.3382,"timestamp":1781049596520,"change":-1,"changeRate":-0.069979,"amplitude":0.151155},"volumeRatio":0.7906582498234361,"optionData":{"bulkOrders":[{"symbol":"SMMT","call":false,"expireDate":1799989200000,"strike":"10.0","timestamp":1781015726435,"price":1.9,"volume":1500,"amount":285000,"type":"-"}]},"impliedVol":0.8025,"impliedVolPercentile":0.26},"requestUrl":"/m/hq/s/SMMT","defaultTab":"news","newsList":[{"id":"1154114279","title":"Summit Therapeutics 融资所得将用于 Ivonescimab 研发、营运资金及一般公司用途","url":"https://stock-news.laohu8.com/highlight/detail?id=1154114279","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154114279?lang=zh_cn&edition=full","pubTime":"2026-06-10 04:48","pubTimestamp":1781038091,"startTime":"0","endTime":"0","summary":"Summit Therapeutics PLC 此次融资筹集的资金，将专项用于其核心在研药物 Ivonescimab 的研发工作、补充公司营运资金，以及满足其他一般性企业用途。此举旨在为公司的关键研发管线提供资金支持，并确保日常运营的财务灵活性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMT","LU2488822045.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159064563","title":"异动解读 | 临床试验数据存疑引发市场担忧，Summit Therapeutics盘中大跌7.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=1159064563","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159064563?lang=zh_cn&edition=full","pubTime":"2026-06-01 21:33","pubTimestamp":1780320830,"startTime":"0","endTime":"0","summary":"Summit Therapeutics（SMMT）今日盘中股价大跌7.41%，引起了市场的广泛关注。消息面上，尽管公司及其中国合作伙伴Akeso的实验性抗癌药物ivonescimab在晚期肺癌临床试验中显示出能延长患者生存期的积极效果，但市场对此反应消极。部分分析师指出，该研究仅在中国进行，其疗效能否在更广泛的全球患者群体（如美国和欧洲）中得到验证仍存在疑问。投资者担忧药物未来在这些关键市场的获批前景，这可能是导致股价承压下跌的主要原因。Summit公司通过一项价值高达500亿美元的协议获得了该药物在美、加、欧、日等地区的权益，此次数据的局限性引发了市场对其长期商业潜力的重新评估。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194620744","title":"异动解读 | 临床试验数据虽积极但存疑，Summit Therapeutics盘前大跌5.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=1194620744","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194620744?lang=zh_cn&edition=full","pubTime":"2026-06-01 21:31","pubTimestamp":1780320713,"startTime":"0","endTime":"0","summary":"Summit Therapeutics（SMMT）今日盘前股价大幅下挫5.25%，引起了投资者的密切关注。消息面上，尽管公司及其中国合作伙伴Akeso的实验性抗癌药物ivonescimab在晚期肺癌临床试验中显示出能延长患者生存期的积极效果，但市场对此反应消极。部分分析师指出，该研究仅在中国进行，其疗效能否在更广泛的全球患者群体中得到验证仍存在疑问。投资者担忧药物未来在美国和欧洲等关键市场的获批前景，这可能是导致股价承压下跌的主要原因。Summit公司通过一项价值高达500亿美元的协议获得了该药物在美、加、欧、日等地区的权益，此次数据的局限性引发了市场对其长期商业潜力的重新评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637341190","title":"H.C. Wainwright下调Summit评级，默沙东ADC数据引发竞争担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=2637341190","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637341190?lang=zh_cn&edition=full","pubTime":"2026-05-23 03:46","pubTimestamp":1779479160,"startTime":"0","endTime":"0","summary":"由于竞争对手默沙东与科伦博泰合作的抗体偶联药物sac-TMT在肺癌治疗中取得积极III期数据，H.C． Wainwright于5月22日将Summit Therapeutics的股票评级从买入下调至中性，并取消了此前23美元的目标价。　　此次下调的核心原因在于，H.C． Wainwright对sac-TMT数据给Summit核心药物ivonescimab带来的竞争压力表示担忧。Summit目前没有任何已上市药物，过去十二个月EBITDA亏损达12.2亿美元，持续处于亏损状态。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-23/doc-inhyvhtz7330931.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","SMMT","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145262250","title":"异动解读 | Summit Therapeutics盘中大跌5.01%，H.c.Wainwright下调目标价叠加临床数据利空","url":"https://stock-news.laohu8.com/highlight/detail?id=1145262250","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145262250?lang=zh_cn&edition=full","pubTime":"2026-05-08 01:15","pubTimestamp":1778174117,"startTime":"0","endTime":"0","summary":"Summit Therapeutics  今日盘中股价大跌5.01%，引起了市场关注。消息面上，此次下跌主要受到两方面因素影响。首先，投行H.c.Wainwright近日将公司目标价从30美元下调至23美元，直接打击了市场信心。其次，公司此前披露的HARMONi-3研究中，针对鳞状非小细胞肺癌的中期无进展生存期分析未达到统计学显著性的成功标准，这一利空消息的影响仍在持续发酵。多家机构相继下调目标价，形成了负面共振效应。公司表示，HARMONi-3研究的最终PFS结果预计将于今年下半年发布。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119497710","title":"异动解读 | Summit Therapeutics盘中大涨5.42%，花旗维持买入评级及ASCO数据预期提振反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1119497710","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119497710?lang=zh_cn&edition=full","pubTime":"2026-05-04 21:54","pubTimestamp":1777902888,"startTime":"0","endTime":"0","summary":"Summit Therapeutics (SMMT) 今日盘中股价大幅上涨5.42%，引起了市场的广泛关注。消息面上，尽管公司此前因HARMONi-3鳞状非小细胞肺癌中期PFS数据未达统计学显著性而股价受挫，但花旗分析师Yigal Nochomovitz在利空公布后仍维持买入评级及40美元目标价，为市场注入了信心。此外，公司与康方生物合作的依沃西单抗即将在ASCO会议上公布HARMONi-6总生存期数据，市场对后续催化事件存在期待，共同推动了此次超跌反弹。公司表示HARMONi-3最终PFS结果将于下半年发布。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100864984","title":"Summit Therapeutics公布2026年第一季度财务业绩及运营进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1100864984","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100864984?lang=zh_cn&edition=full","pubTime":"2026-05-01 04:33","pubTimestamp":1777581201,"startTime":"0","endTime":"0","summary":"Summit Therapeutics PLC（纳斯达克代码：SMMT）近日披露了截至2026年3月31日的第一季度财务报告及业务发展动态。\n公司在本季度持续推进核心研发管线，重点聚焦创新疗法的临床开发。管理层在财报中强调了关键项目的里程碑进展，同时概述了战略布局与资金配置情况。\n财务方面，季报详细呈现了营收状况、研发投入及现金流表现。公司表示将保持稳健的财务管控，以支持长期研发目标与商业化准备。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","SMMT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622426438","title":"英国汽车制造商和贸易商协会：出口疲软导致英国2月汽车产量大幅下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2622426438","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622426438?lang=zh_cn&edition=full","pubTime":"2026-03-27 17:30","pubTimestamp":1774603800,"startTime":"0","endTime":"0","summary":"英国汽车制造商和贸易商协会数据显示，英国2月汽车产量大幅下滑，这凸显出该行业面临的压力日益加剧，而此时伊朗冲突尚未给英国制造业前景蒙上更深层的阴影。　　该协会数据显示，英国汽车产量同比下降17.2%，至68061辆。　　协会数据同时显示，欧盟仍是英国汽车工厂全球最大的出口市场，吸纳了英国64%的汽车出口量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/world/2026-03-27/doc-inhsmnzv8304933.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","LU2488822045.USD","SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107476933","title":"Summit Therapeutics盘前大涨5.5% 美国FDA受理其Ivonescimab上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1107476933","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107476933?lang=zh_cn&edition=full","pubTime":"2026-01-29 20:36","pubTimestamp":1769690215,"startTime":"0","endTime":"0","summary":"Summit Therapeutics PLC股价在盘前交易中强势攀升5.5%，此前美国食品药品监督管理局正式受理了该公司提交的双特异性抗体药物Ivonescimab的新药上市申请。\n这一关键监管里程碑的达成，为这款创新肿瘤免疫疗法的审评进程铺平了道路，同时也显著提振了市场投资者对该公司未来发展前景的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMT","BK4139","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142715038","title":"Summit Therapeutics宣布美国FDA受理Ivonescimab联合化疗治疗EGFR突变非小细胞肺癌患者TKI治疗后生物制品许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1142715038","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142715038?lang=zh_cn&edition=full","pubTime":"2026-01-29 20:31","pubTimestamp":1769689877,"startTime":"0","endTime":"0","summary":"Summit Therapeutics PLC宣布，美国食品药品监督管理局（FDA）已正式受理其提交的生物制品许可申请（BLA）。该申请旨在寻求批准Ivonescimab与化疗联合，用于治疗表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）患者，这些患者此前已接受过酪氨酸激酶抑制剂（TKI）治疗。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","SMMT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190691688","title":"Summit Therapeutics：双方保留各自产品权益，协议具有双向非排他性","url":"https://stock-news.laohu8.com/highlight/detail?id=1190691688","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190691688?lang=zh_cn&edition=full","pubTime":"2026-01-12 19:18","pubTimestamp":1768216682,"startTime":"0","endTime":"0","summary":"根据最新合作协议条款，Summit Therapeutics PLC（以下简称Summit）与其合作伙伴将保持对各自研发产品的完整所有权。该协议采用双向非排他性模式，意味着双方均可独立开展与其他实体的合作，同时保留对自有知识产权的绝对控制权。\n这一安排既保障了双方在特定领域的自主运营空间，又为未来潜在的战略协同留下弹性。非排他性条款尤其凸显了合作框架的灵活性，允许各方在遵守协议基础上自由探索多元化的商业机会。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0161305163.EUR","LU0109981661.USD","LU2488822045.USD","LU1228905540.USD","LU0575583348.USD","LU1302929846.USD","LU0225771236.USD","LU1400636657.SGD","LU0203345920.USD","IE00B3T34201.USD","GSK.UK","LU0225284248.USD","BK5011","LU1400636491.USD","LU0306806265.USD","IE00BQJZX424.USD","LU1400636574.HKD","LU1309081286.SGD","LU0306807586.USD","LU0971552830.HKD","IE0034235071.USD","LU1481600234.SGD","LU1064927863.SGD","LU0971552673.USD","LU1202635105.USD","LU1487256676.USD","SMMT","LU1481599808.USD","LU0289739699.SGD","BK4139","LU1645745479.HKD","IE00BWDBJ516.SGD","LU0058720904.USD","LU1015430645.USD","LU1098665638.USD","LU1228905037.USD","LU0985481810.HKD","LU0321505439.SGD","LU0545562505.USD","LU1035777561.USD","LU0203347892.USD","LU1670756490.USD","LU1046248800.SGD","LU0321505868.SGD","LU0211331839.USD","LU1983299246.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601485265","title":"50亿英镑折扣撬动市场！英国2025年新车销量重回200万辆 中国品牌加速崛起","url":"https://stock-news.laohu8.com/highlight/detail?id=2601485265","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601485265?lang=zh_cn&edition=full","pubTime":"2026-01-06 10:25","pubTimestamp":1767666309,"startTime":"0","endTime":"0","summary":"英国汽车制造商和贸易商协会周二公布的数据显示，2025年新车注册量增长3.5%，达到202万辆。中国汽车日益增长的受欢迎度助力英国汽车销量重回200万辆以上水平，其更亲民的价格吸引了消费者。英国对中国品牌尤其具有吸引力，因为它没有效仿欧盟对中国制造的电动汽车加征关税。这家英国最大的汽车制造商被迫停产近六周，促使政府出面提供15亿英镑的紧急贷款担保，以帮助陷入困境的供应商。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389041.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","SMMT","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518436278","title":"Summit Therapeutics Inc.盘中异动 股价大跌5.91%报16.73美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518436278","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518436278?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:31","pubTimestamp":1741613469,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时31分，Summit Therapeutics Inc.股票出现异动，股价急速跳水5.91%。截至发稿，该股报16.73美元/股，成交量9.1706万股，换手率0.01%，振幅0.81%。Summit Therapeutics Inc.股票所在的生物技术行业中，整体跌幅为0.59%。Summit Therapeutics Inc.公司简介：Summit Therapeutics Inc是一家生物制药公司，专注于发现、开发和商业化用于严重传染病的新型抗生素。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021310998a29c8c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021310998a29c8c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SMMT","LU2488822045.USD","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517516510","title":"Summit Therapeutics Inc.盘中异动 早盘股价大跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517516510","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517516510?lang=zh_cn&edition=full","pubTime":"2025-03-06 22:34","pubTimestamp":1741271643,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日22时34分，Summit Therapeutics Inc.股票出现波动，股价急速下跌5.06%。截至发稿，该股报18.56美元/股，成交量5.6688万股，换手率0.01%，振幅2.05%。Summit Therapeutics Inc.股票所在的生物技术行业中，整体跌幅为0.64%。Summit Therapeutics Inc.公司简介：Summit Therapeutics Inc是一家生物制药公司，专注于发现、开发和商业化用于严重传染病的新型抗生素。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223403abeb7870&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223403abeb7870&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LU2488822045.USD","LENZ","SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516650980","title":"Summit Therapeutics Inc.盘中异动 急速下跌5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516650980","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516650980?lang=zh_cn&edition=full","pubTime":"2025-03-04 03:36","pubTimestamp":1741030563,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日03时36分，Summit Therapeutics Inc.股票出现异动，股价快速下跌5.12%。Summit Therapeutics Inc.股票所在的生物技术行业中，整体涨幅为0.64%。其相关个股中，Bioxcel Therapeutics, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Biocardia, Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Allarity Therapeutics, Inc.、Entero Therapeutics Inc.较为活跃，换手率分别为4550.84%、206.83%、181.58%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Radiopharm Theranostics Limited、Entero Therapeutics Inc.，振幅分别为206.20%、119.50%、70.53%。Summit Therapeutics Inc.公司简介：Summit Therapeutics Inc是一家生物制药公司，专注于发现、开发和商业化用于严重传染病的新型抗生素。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503040336039637f047&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503040336039637f047&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","LENZ","BK4139","SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514376555","title":"Summit Therapeutics Inc.盘中异动 早盘大幅拉升5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514376555","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514376555?lang=zh_cn&edition=full","pubTime":"2025-02-28 23:26","pubTimestamp":1740756399,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日23时26分，Summit Therapeutics Inc.股票出现异动，股价急速拉升5.08%。Summit Therapeutics Inc.股票所在的生物技术行业中，整体涨幅为0.36%。其相关个股中，Bioxcel Therapeutics, Inc.、Revolution Medicines Inc C/Wts 17/12/2026 、Puma Biotechnology Inc涨幅较大，Bioxcel Therapeutics, Inc.、Enveric Biosciences, Inc.、Virpax Pharmaceuticals, Inc.较为活跃，换手率分别为1430.83%、405.61%、337.95%，振幅较大的相关个股有Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Nrx Pharmaceuticals Inc C/Wts 24/05/2026 、Bioxcel Therapeutics, Inc.，振幅分别为46.60%、43.37%、38.73%。Summit Therapeutics Inc.公司简介：Summit Therapeutics Inc是一家生物制药公司，专注于发现、开发和商业化用于严重传染病的新型抗生素。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228232639a2580f75&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228232639a2580f75&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LU2488822045.USD","LENZ","SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514238400","title":"Summit Therapeutics Inc.2024财年实现净利润-2.21亿美元，同比增加64.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514238400","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514238400?lang=zh_cn&edition=full","pubTime":"2025-02-28 00:01","pubTimestamp":1740672061,"startTime":"0","endTime":"0","summary":"2月28日，Summit Therapeutics Inc.公布财报，公告显示公司2024财年净利润为-2.21亿美元，同比增加64.07%；其中营业收入为0.00美元，每股基本收益为-0.31美元。机构评级：截至2025年2月28日，当前有6家机构对Summit Therapeutics Inc.目标价做出预测，其中目标均价为35.33美元，其中最低目标价为30.00美元，最高目标价为44.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228000106abdf84f2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228000106abdf84f2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514867183","title":"Summit Therapeutics Inc.盘中异动 大幅上涨5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514867183","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514867183?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:32","pubTimestamp":1740666751,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时32分，Summit Therapeutics Inc.股票出现异动，股价急速拉升5.22%。截至发稿，该股报19.26美元/股，成交量5.4943万股，换手率0.01%，振幅3.20%。Summit Therapeutics Inc.股票所在的生物技术行业中，整体涨幅为0.31%。Summit Therapeutics Inc.公司简介：Summit Therapeutics Inc是一家生物制药公司，专注于发现、开发和商业化用于严重传染病的新型抗生素。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223231a2567a36&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223231a2567a36&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","LU2488822045.USD","SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514851874","title":"Summit Therapeutics Inc.盘中异动 早盘股价大涨5.30%报19.07美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514851874","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514851874?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:51","pubTimestamp":1740581499,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日22时51分，Summit Therapeutics Inc.股票出现异动，股价大幅拉升5.30%。截至发稿，该股报19.07美元/股，成交量19.9915万股，换手率0.03%，振幅3.75%。Summit Therapeutics Inc.股票所在的生物技术行业中，整体跌幅为0.08%。Summit Therapeutics Inc.公司简介：Summit Therapeutics Inc是一家生物制药公司，专注于发现、开发和商业化用于严重传染病的新型抗生素。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226225139a254fbaf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226225139a254fbaf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","BK4139","LENZ","SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514155760","title":"Summit Therapeutics Inc.盘中异动 早盘快速下跌5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514155760","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514155760?lang=zh_cn&edition=full","pubTime":"2025-02-25 23:14","pubTimestamp":1740496489,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日23时14分，Summit Therapeutics Inc.股票出现异动，股价大幅下跌5.07%。截至发稿，该股报17.89美元/股，成交量95.9436万股，换手率0.13%，振幅6.37%。Summit Therapeutics Inc.股票所在的生物技术行业中，整体涨幅为0.82%。Summit Therapeutics Inc.公司简介：Summit Therapeutics Inc是一家生物制药公司，专注于发现、开发和商业化用于严重传染病的新型抗生素。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022523144998925689&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022523144998925689&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LU2488822045.USD","SMMT","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.smmttx.com","stockEarnings":[{"period":"1week","weight":-0.0384},{"period":"1month","weight":-0.2096},{"period":"3month","weight":-0.1113},{"period":"6month","weight":-0.2057},{"period":"1year","weight":-0.3372},{"period":"ytd","weight":-0.183}],"compareEarnings":[{"period":"1week","weight":-0.0296},{"period":"1month","weight":-0.0008},{"period":"3month","weight":0.0898},{"period":"6month","weight":0.0695},{"period":"1year","weight":0.2291},{"period":"ytd","weight":0.0808}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Summit Therapeutics Inc.于2013年11月22日在英格兰和威尔士注册成立，特拉华州的一家公司（“New Summit”）已成为该公司的后续发行方。该公司是一家生物制药公司，专注于发现、开发和商业化对患者、医生、护理人员和社会友好的药物疗法，旨在提高生活质量，延长潜在寿命，并解决严重的未满足的医疗需求。该公司的候选产品管线的设计目标是成为肿瘤治疗领域中对患者友好的、新时代的标准护理药物。","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.093233},{"month":2,"riseRate":0.454545,"avgChangeRate":0.0357},{"month":3,"riseRate":0.454545,"avgChangeRate":0.039344},{"month":4,"riseRate":0.5,"avgChangeRate":0.042597},{"month":5,"riseRate":0.5,"avgChangeRate":0.075963},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.094936},{"month":7,"riseRate":0.636364,"avgChangeRate":0.088383},{"month":8,"riseRate":0.454545,"avgChangeRate":-0.007003},{"month":9,"riseRate":0.363636,"avgChangeRate":0.075404},{"month":10,"riseRate":0.272727,"avgChangeRate":-0.047867},{"month":11,"riseRate":0.363636,"avgChangeRate":-0.015842},{"month":12,"riseRate":0.454545,"avgChangeRate":0.356783}],"exchange":"NASDAQ","name":"Summit Therapeutics PLC","nameEN":"Summit Therapeutics PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Summit Therapeutics PLC(SMMT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Summit Therapeutics PLC(SMMT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Summit Therapeutics PLC,SMMT,Summit Therapeutics PLC股票,Summit Therapeutics PLC股票老虎,Summit Therapeutics PLC股票老虎国际,Summit Therapeutics PLC行情,Summit Therapeutics PLC股票行情,Summit Therapeutics PLC股价,Summit Therapeutics PLC股市,Summit Therapeutics PLC股票价格,Summit Therapeutics PLC股票交易,Summit Therapeutics PLC股票购买,Summit Therapeutics PLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Summit Therapeutics PLC(SMMT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Summit Therapeutics PLC(SMMT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}